Kirchgraber Paul R 4
4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed May 23, 2023
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Exercise/Conversion
Common Stock
2023-05-19$182.51/sh+4,300$784,793→ 17,246 total - Sale
Common Stock
2023-05-19$216.91/sh−4,300$932,707→ 12,946 total - Exercise/Conversion
Non-qualified Stock Options
2023-05-19−4,300→ 0 totalExercise: $182.51From: 2021-02-04Exp: 2030-02-03→ Common Stock (4,300 underlying)
Footnotes (2)
- [F1]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- [F2]The option vested in three equal annual installments beginning on the date reflected in this column.